Intervention

KF-0210 (dosage RP2D-1) + Atezolizumab

ClinicalTrials.gov intervention label

Clinical trials1

Recruiting0

Common conditions6

Lead sponsors shown1

Clinical trials

1 shown

A Study of KF-0210 in Advanced Solid Tumors PatientsNCT04713891 · 2021-03-09

COMPLETED

Common conditions

Advanced Solid Tumor1 Bladder Cancer1 Colorectal Cancer1 Gastric Cancer1 Lung Cancer1 Squamous Cell Carcinoma of the Esophagus1

Leading sponsors

Keythera Pharmaceuticals (Australia) Pty Ltd1

Trial status mix

COMPLETED1

Phase mix

PHASE11

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.